In case anyone wishes to comment re the tribunal final decision, I'm posting this.
The case against Advanz Pharma and its previous owners by the Competition and Markets Authority (CMA) is finally over.
Advanz Pharma appealed against the fines imposed by the CMA and the case was heard today.
The Competition Appeal Tribunal has upheld the CMA's findings against Advanz Pharma and its former owners but have reduced the fines given previously.
Thyroid UK is disappointed that the fines have been reduced as these companies have caused untold damage to all patients who need liothyronine because of the price hikes.
Thyroid UK and other thyroid organisations are still campaigning to gain access for thyroid patients who need this medication especially since the latest guidance by NHS England and the British Thyroid Association have been published.
You can read the whole tribunal case here:
catribunal.org.uk/sites/cat...
Please try to keep comments on topic and not overtly political.
The conclusion is on page 173 (PDF page numbering):
497. For the reasons set out above, the Tribunal:
(1) dismisses the Appellants’ appeals against the CMA’s decision that
Advanz abused its dominant position by charging excessive and unfair
prices for Liothyronine Tablets during the Infringement Period;
(2) reduces the penalty payable by the Cinven Appellants from £51.9 million
to £37.1 million; and
(3) reduces the penalty payable by Hg from £8.6 million to £6.2 million.
498. This judgment is unanimous.